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Background: Levosimendan improves clinical and hemodynamic parameters exerting an anti-inﬂammatory and
antiapoptotic effect in decompensated heart failure. The aim of this study was to evaluate the effects of
levosimendan on LV torsion, plasma levels of NT-proBNP and on the balance between pro-inﬂammatory (TNF-α,
IL-6) and anti-inﬂammatory cytokines (IL-10).
Methods:We enrolled 24 patients (age 62 ± 7 years) with acute HF, NYHA class IV and severe LV dysfunction. All
patients underwent transthoracic echocardiography using two-dimensional speckle tracking analysis to detect LV
twist angle (LVTA), at baseline and 1 week after treatment with levosimendan infusion. Biochemical parameters
(pro-BNP, IL-6, IL-10, TNF-α) were determined by enzyme-linked immunosorbent (ELISA).
Results:After oneweek, we observed an improvement in LV function especially in LVTA (4.15± 2.54 vs 2.9± 2.1
p b 0.01), in LV ejection fraction (27.3 ± 8.04 vs 21.6 ± 6.8 p = 0.03) and also a signiﬁcant reduction in BNP
levels (1844 ± 560 vs 4713 ± 1050, p = 0.03). The multiple linear regression analysis showed a signiﬁcant re-
lation between a reduction of TNFα/IL-10 ratio (Δ N 20%) and BNP (Δ N 40%), LVEF (Δ N 10%) and LVTA (Δ N 20%)
(O.R. 1.77, 95% C.I. 1.11–2.83; O.R. 1.49, 95% C.I. 1.08–2.67; O.R. 1.66, 95% C.I. 1.10–2.74, respectively, conﬁrmed
p, all b0.01 by Hosmer–Lemeshov conﬁrmation and the formal test for interaction).
Conclusions: Levosimendan exerts a hemodynamic effect by improving EF and LV torsion in patients with
acute HF in association with a positive effect on the balance between pro and anti-inﬂammatory cytokines.© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Levosimendan is a calcium sensitizing drug that improves cardiac
contractility in systole without impairing relaxation in diastole. This
drug may also have a vasodilator action which results in improved
cardiac output without increasing myocardial oxygen consumption.
An active metabolite of this drug (OR1896) maintains the clinical re-
sponse for up to 9 days from the end of the continuous infusion [2].
The clinical effect of levosimendan, mainly in terms of reducedmor-
tality or prolonged bridging window to non-medical therapies for
advanced heart failure (HF), is still under debate but its efﬁcacy in
several settings of cardiovascular disease is likely to be proven in various
studies [3].
Left ventricular (LV) torsion is a fundamental component of the nor-
mal LV systolic contraction that plays an important role to optimize LVliclinico SantaMaria alle Scotte”,
fax: +39 0577 586185.
is an open access article under the Cejection fraction (LVEF). It arises from the reciprocal rotation of the LV
apex and base during systole, created by the contraction of its oblique
spiral ﬁbers. The evaluation of LV twist angle (LVTA) has been possible
by speckle tracking echocardiography (STE) analyzing the net differ-
ence in mean rotation between the apex (counterclockwise) and the
base (clockwise) [4]. STE has recently been proposed and validated as
a feasible method for measuring LV rotation and torsion [5].
Levosimendan also seems to have anti-inﬂammatory and anti-
apoptotic properties in decompensated heart failure [1]. Pro-
inﬂammatory cytokines like IL-6 and TNF-α depress myocardial con-
tractility, promote cardiomyocyte apoptosis and contribute to cardiac
remodeling [6–8].
The activity of inﬂammatory cytokines is also inﬂuenced by anti-
inﬂammatory molecules such us interleukin (IL-10) which can down-
regulate the production of several inﬂammatorymediators frommacro-
phages and other immune cells [9].
The aim of this study was to investigate the role of levosimendan on
systolic function especially on myocardial torsional dynamics and on
biochemical parameters like brain natriuretic peptide (BNP) levels and
on pro/anti-inﬂammatory cytokine imbalance.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1. Study population
We enrolled twenty-four consecutive patients (age 62 ± 7 years)
with acute NYHA class IV heart failure and severe LV dysfunction
(LVEF b 30%). Informed consent was obtained from all subjects and the
protocol was approved by the ethics committee of the recruiting center
as an extensionof previous authorization for similar experimentalmodels
[12]. Exclusion criteria were: systolic blood pressure b 80 mm Hg, heart
rate N 130 bpm, recent myocardial infarction (b8 weeks) or active
myocardial ischemia, serum creatinine levels higher than 2.5 mg/dl (or
glomerular ﬁltration rate less than 30ml/min) or dialysis, hepatic failure,
acute or chronic infectious or inﬂammatory diseases. All patients were on
appropriate medical therapy including beta-blockers, ACE-inhibitors and
diuretics and all patients were treated additionally with continuous 24-h
infusion of levosimendan at 0.1 μg/kg/min without an intravenous load-
ing dose (see Table 1 for details).2.2. Standard echocardiography
Echocardiographic studies were performed using a high quality por-
table echocardiograph (Vivid i GE USA) equippedwith a 2.5MHz trans-
ducer. Subjects were studied in the left lateral recumbent position.
Echocardiography was performed by experienced physicians at
baseline and one week after levosimendan treatment. Measurements
of LV end diastolic and end systolic volumes (LV EDVand LVESV respec-
tively), left atrial dimensions, LVEF and diastolic LV ﬁlling were made in
accordancewith current recommendations of ASE [10]. LVEF, measured
using the biplane modiﬁed Simpson's method, was employed as a stan-
dard index of global LV systolic function. LV diastolic function was esti-
mated by pulsedwave (PW)Doppler on transmitralﬂowassessingpeak
velocities in early (E) and late diastole (A), E/A ratio.2.3. Tissue Doppler imaging and M-mode annulus excursion analysis
Left ventricular longitudinal function was explored by pulsed tissue
Doppler imaging, placing the sample volume at the level ofmitral lateral
annulus from the apical four chamber view. Peak systolic (Sm), early
diastolic (Em), and late diastolic (Am) annular velocities were obtained.
The E/Em ratio was also calculated and used as index of LV ﬁlling pres-
sures. M-mode measurements of mitral annular plane systolic excur-
sion (MAPSE) were performed by placing the cursor perpendicular to
the lateral site of the annulus. Tricuspid annular plane systolic excursion
(TAPSE) was also measured using two dimensional guided M-mode
imaging [11].Table 1
Clinical characteristics of the study population.
Age (years) 62 ± 7
Sex, male 8 (44%)
New York Heart Association IV (100%)
Ischemic/Non ischemic patients 12/12 (50%)
Medicaments
Diuretics 24 (100%)
Angiotensin converting enzyme inhibitors 14/24 (58%)
Angiotensin receptor blockers 10/24 (42%)
Beta-blocker 8/24 (33%)
Statins 12/24 (50%)
Antiaggregants 12/24 (50%)
Spironolactone 8/24 (33%)
Qualitative values are expressed as %. No statistical signiﬁcant differences were found
between ischemic and non-ischemic dilated cardiomyopathy.2.4. Speckle tracking echocardiography
For the assessment of LVTA, LV short-axis planes were obtained at
basal and apical levels at adequate frame rates (range 60–90 fps). The
basal plane was deﬁned at the level of the mitral valve, whereas the
apical plane was acquired distally to the papillary muscles.
STE analysis was performed using a dedicated software (Echo Pac,
GE USA). After manual delineation of LV endocardial border using a
point-and-click approach a second epicardial tracing was automatically
generated by the system. The software automatically segmented the LV
circumference into six myocardial segments generating rotation curves
for each segment. Two mean LV rotation curves representing basal and
apical rotationwere obtained. LVTAwas calculated as the net difference
inmean rotation between the apical and basal levels. LV untwisting rate
was calculated as the early diastolic peak time derivative of the time-
twisting angle curve [12].
2.5. Biochemical measurements
Peripheral venous blood samples were collected by a 19 gauge nee-
dle without stasis at baseline and one week after treatment with
levosimendan infusion to detect cytokine levels (IL-6, IL-10, TNF-α)
measured by enzyme-linked immunosorbent assay (ELISA) and plasma
BNP levels using the bedside device Triage BNP test (Biosite San Diego,
CA) as previously described [12].
2.6. Statistical analysis
Statistical analysis was performed using the SPSS 12.0 statistical
package for Windows. Quantitative values were expressed as mean ±
standard deviation and qualitative values as %. The Wilcoxon's paired
test was used to compare values before and after drug administration.
A two-tailed p value b 0.05 was considered signiﬁcant.
Amultiple logistic regression analysis was employed to evaluate the
putative relations among studied variables once corrected for basic
(age, BMI, pharmacological treatments and other established diagnosis)
and measurable parameters changes evaluated during the study (PAS,
PAD, heart rate, LVEF, LVTA). In particular we categorized a 5% growing
differences range (both positive or negative trend, 0–4.9, 5–9.9, 10–
14.9% and so on) in parameters of cardiac function (LVESV, LVEDV,
LVEF, LVTA and BNP) as the primary end-point to relate with TNFα,
IL6, IL10 and each to other ratios. Furthermore the statistical model
consisting of a formal test for interaction was employed to determine
the putative interaction for each single variable. Brieﬂy, starting from lo-
gistic regression analysis in which Y was the parametric obtained mod-
iﬁcation of each single evaluated parameter; the variables X1 and X2
were the present or not (1 or 0) of categorized ranges of cytokinemod-
iﬁcations andX3 the combination. The simpliﬁed formula for calculation
was: Y= β0+ β1X1+ β2X2+ β3X3 and the null hypothesis was test-
ed as H0:β3 = 0. Final validation of data was assessed by a resampling
technique (Exact Tests in SPSS 2003 module) and discrimination analy-
sis by the Hosmer–Lemeshow method [G2HL =∑10J = 1 (Oj− Ej)2 /
Ej (1 − Ej/nj) ~ X28] where nj = number of observations in the jth
group, Oj =∑1yij = observed number of positive cases in the jth
group, Ej=∑pij= expected number of positive cases in the jth group.
3. Results
After one week, clinical, echocardiographic and neurohumoral
controls were performed. The general characteristics and echocar-
diographic parameters of the studied patients are summarized in
Tables 1–3 respectively.
Echocardiographic and speckle tracking evaluation after one week
from the end of treatment demonstrated a signiﬁcant improvement of
LV systolic function resulting in an increase of LVEF (27.3 ± 8.04 vs
Table 2
Echocardiographic and speckle tracking data pre- and post-treatment with levosimendan.
Parameters Baseline
(N = 24)
One week
(N = 24)
p value
LVEDD (mm) 75.5 ± 11.52 75.25 ± 11.14 p = ns
LVESD (mm) 65.1 ± 10.7 64.62 ± 10.11 p = ns
LVEDV (ml) 314.12 ± 160 280.8 ± 96.95 p = ns
LVESV (ml) 226 ± 125 216.75 ± 82.10 p = ns
LVEF (%) 21.6 ± 6.8 27.3 ± 8.04 p = 0.03
E (m/s) 0.78 ± 0.2 0.77 ± 0.2 p = ns
A (m/s) 0.3 ± 0.7 0.55 ± 0.2 p = ns
Em (m/s) 0.04 ± 0.01 0.05 ± 0.007 p = ns
Am (m/s) 0.07 ± 0.02 0.09 ± 0.04 p = ns
MAPSE (mm) 9 ± 2 11.25 ± 4.02 p = ns
LV twist angle (°) 2.9 ± 2.1 4.1 ± 2.5 p = 0.01
LV untwisting −39 ± 36.2 −35.9 ± 22 p = ns
Strain circumference apex (%) −5.76 ± 2.4 −5.98 ± 2.6 p = ns
Strain circumference base
(%)
−4.29 ± 2.2 −5.35 ± 1.9 p = ns
PVLS (%) 6.3 ± 3 7.3 ± 3.3 p = ns
PALS (%) 9.3 ± 7.3 12 ± 4.7 p = ns
Data are expressed as mean ± standard deviation. Quantitative values were expressed as
mean ± standard deviation. TheWilcoxon's paired test was used to compare values before
and after drug administration. A p value b 0.05 was considered signiﬁcant.
Abbreviations: LVEDDand LVESD left ventricle end-diastolic and end-systolic diameter re-
spectively, LVESV left ventricle end-systolic volume, LVEDV left ventricle end diastolic
volume, E early rapidﬁllingwave, A ﬁllingwave due to atrial contraction, Em early diastol-
ic annular velocities, Am late diastolic annular velocities, PVLS peak longitudinal strain of
left ventricle, and PALS peak longitudinal strain left atrium.
Fig. 1. Variation in LV ejection fraction after treatment with levosimendan. Quantitative
values were expressed as mean ± standard deviation. The Wilcoxon's paired test was
used to compare values before and after drug administration. A p value b 0.05 was consid-
ered signiﬁcant.
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(Figs. 1 and 2).
Even M-mode mitral annular plane systolic excursion (MAPSE),
peak of left ventricle longitudinal strain (PVLS) and peak left atrium
longitudinal strain (PALS) were not signiﬁcantly increased (Table 2).
We also observed a signiﬁcant reduction in BNP levels after one week
from the end of levosimendan infusion (1844 ± 560 vs 4713 ± 1050,
p = 0.03). Furthermore, a signiﬁcant decrease of TNF-α and IL-6 was
observed after one week on treatment with levosimendan (8.9 vs 13.1
pg/ml and 8.3 us 11.6 respectively, both p b 0.05) whereas IL-10 was
signiﬁcantly increased (p b 0.001) (Fig. 3 and Table 3).
Moreover we found a linear correlation between reduction of TNF-
α/IL-10 ratio and reduction on BNP levels at one week (r = 0.49, p =
0.0001 if increase of IL-10 was more of 20%).
It was also demonstrated a negative correlation between LVEF and
TNF-α/IL-10 ratio (r = -0.44, p b 0.01 if increase of IL-10 N 20%) and a
negative correlation between LVTA and TNF-α/IL-10 ratio (r =−0.44
p b 0.0089). Finally there were no adverse effects of levosimendan treat-
ment in our patient population.
The multiple linear regression analysis showed a signiﬁcant relation
only between a reduction of TNF α/IL-10 ratio (Δ N 20%) and BNP (Δ N
40%), LVEF (Δ N 10%) and LVTA (Δ N 20%) (O.R. 1.77, 95% C.I. 1.11–
2.83; O.R. 1.49, 95% C.I. 1.08–2.67; O.R. 1.66, 95% C.I. 1.10–2.74, respec-
tively, conﬁrmed p, all b0.01 by Hosmer–Lemeshov conﬁrmation and
the formal test for interaction).Table 3
Cytokines and BNP values pre- and post-one week from treatment with levosimendan.
Parameters Baseline One week p value
IL-6 (pg/ml) 11.6 ± 1.4 8.3 ± 0.9 p b 0.05
IL-10 (pg/ml) 5.8 ± 0.5 8.8 ± 0.7 p b 0.001
TNF-α (pg/ml) 13.1 ± 1.9 8.9 ± 0.8 p b 0.05
TNF- α/IL-10 ratio 2.22 ± 1.6 1.01 ± 0.6 p b 0.01
BNP (pg/ml) 4713 ± 1050 1844 ± 560 p = 0.03
Data are expressed asmean ± standard deviation. TheWilcoxon's paired testwas used to
compare values before and after drug administration. A p value b 0.05 was considered
signiﬁcant.
Abbreviations: BNP brain natriuretic peptide, IL interleukin.4. Discussion
Levosimendan induced changes in hemodynamic and clinical
parameters. Additionally the effect of this treatment in patients with
heart failure has been shown to be reﬂected in change in plasma con-
centrations of neurohormonal and inﬂammatory markers [11].
In the present study a cohort of patients with decompensated heart
failurewas treatedwith the calcium sensitizer levosimendan and clinical,
echocardiographic and laboratory parameters were evaluated to further
assess the putative clinical beneﬁt of this drug.4.1. Echocardiographic and speckle tracking examination
Levosimendan improves echocardiographic indexes of systolic func-
tion after seven days from the end of treatment. Our study demonstrat-
ed an increase in LVEF and in LV torsional dynamics in patients with
acute heart failure and treated with levosimendan. Previous studies
have demonstrated that levosimendan improves LV systolic and diastol-
ic function [13]. LV systolic contraction is a complex phenomenon
resulting from interaction among different myocardial layers, leading
to simultaneous longitudinal and circumferential shortening, radial
thickening and twisting [14]. Left ventricular twisting is a component
of the normal LV systolic contraction and represents the instantaneousFig. 2. Increase of LV twist angle after levosimendan. Quantitative values were expressed
as mean ± standard deviation. The Wilcoxon's paired test was used to compare values
before and after drug administration. A p value b 0.05 was considered signiﬁcant.
Fig. 3. Decreased levels of BNP after treatment with levosimendan. Quantitative values
were expressed as mean ± standard deviation. The Wilcoxon's paired test was used to
compare values before and after drug administration. A p value b 0.05 was considered
signiﬁcant.
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able to generate a wringing motion of the LV that drives the blood
out of LV cavity. Indeed during contraction the subendocardial and
subepicardial layers oppose each others due to their oblique ﬁber
angle orientations but greater force is generated in the epicardial layers
as a result of the longer distance from the center of the ventricle. So the
epicardial ﬁbers govern the direction of LV twist determining a counter-
clockwise torsional movement during systolic ejection. In the dilated
heart the left ventricle takes a spherical geometry and this determines
the loss of oblique architecture of loop ﬁbers and leads to impair LV
torsional movement. The reduction of twisting motion would increase
endocardial stress and, therefore, increase oxygen demand, thereby re-
ducing the efﬁciency of LV systolic function. Levosimendanwith its ino-
tropic effect increases myocardial contractility of the subendocardial
and subepicardial ﬁbers and, in that way, determines an improvement
in LV torsion dynamics that allows a reduction in oxygen consumption.
4.2. Neurohormonal response to levosimendan
In our patient population, levosimendan resulted in a signiﬁcant
reduction of BNP and pro-inﬂammatory cytokine (TNF-α, IL-6) circulat-
ing levels after one week from the end of treatment. This reduction was
accompanied by a signiﬁcant increase of LVEF and LV twisting.
It iswell known that overexpression of circulatingpro-inﬂammatory
cytokines leads to increased oxidative stress and enhanced cardiomyo-
cyte and endothelial cell apoptosis and plays an important role in the
clinical and hemodynamic deterioration of heart failure [15]. At the
same time overproduction of BNP in heart failure is a result of elevated
end-diastolic cardiac wall stress. High levels of BNP and IL-6 are inde-
pendent risk factors for morbidity and mortality in patients with heart
failure, despite an improvement in LVEF and symptoms after medical
therapy [16].
In the present study we demonstrated that levosimendan plays an
important role in the imbalance between pro- and anti-inﬂammatory
cytokines: it reduces the levels of IL-6 and TNF-α and increases the
anti-inﬂammatory IL-10 levels that can downregulate the production
of several inﬂammatory mediators from macrophages and other im-
mune cells [8].
In our study we found an important reduction of TNF-α/IL-10 ratio
that showed a signiﬁcant correlation with LV twist, so we can conﬁrm
that levosimendan has an inotropic and anti-inﬂammatory role also
in the setting of non-ischemic dilated cardiomyopathy (50% of our
patients) with respect to post-ischemic dilated cardiomyopathy aspreviously demonstrated and actually conﬁrmed [12]. The anti-
inﬂammatory effects of levosimendan could be related to an indirect ac-
tion on circulating cytokines mediated by the improvement of cardiac
hemodynamics. However previous evidences have described as a rele-
vant pathogenetic mechanism the imbalance between pro- and anti-
inﬂammatory cytokines involved even before the development of HF
in the initial stages of ischemic acute coronary syndromes [17].
Thus, a direct anti-inﬂammatory effect of levosimendan can be
strongly suggested according to the previous demonstration of down-
regulation of apoptosis signaling mechanism through inhibition of
TNF-α receptor superfamily and Fas/fas ligand systemwith subsequent
positive effect on cardiomyocytes loss as a consequence of apoptotic cell
death [12].
Taking into account that the effects of levosimendan in our study
have been ascertained in a population of on topmedical treated subjects,
including several molecules known to exert an anti-inﬂammatory effect
[18] (see Table 1), the incremental positive effect on cytokine imbalance
is more likely due to a direct effect than to an indirect one linked to
changes in cardiac hemodynamics.
The positive effect of levosimendan in neurohormonal balance has
been suggested also for repeated infusionswhen a clinical improvement
was established in terms of HF progression with a positive trend for
1-year mortality [18]. Furthermore the treatment with levosimendan
has been suggested to reach an economically positive proﬁle in acute
HF [18].
5. Conclusions
Levosimendan exerts a positive effect on hemodynamic and clinical
parameters improving myocardial contractility without increasing
myocardial oxygen consumption. In patients with advanced heart
failure the increase of LV torsional dynamics appears to be a compensa-
tory mechanism of the failing heart.
Our study demonstrates that levosimendan also induces changes in
neurohumoral markers having a beneﬁcial inﬂuence in the balance be-
tween pro- and anti-inﬂammatory cytokines and in cardiac remodeling
in patients with HF of ischemic or other etiology.
6. Limitations
An important limitation of the clinical use of STE is that to obtain cor-
rect endocardial border delineation an adequate echocardiographic
view is recommended and furthermore STE is closely dependent from
heart rate and it is not possible to conduct strain measurements in pa-
tients with non-sinus rhythms. Furthermore, the latter reduces the
number of eligible patients in the setting of HF.
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